SecBot SecBot
SECBOTREPLAY Home › Report › BSX

BSX · The Federal Circuit affirmed the District of New Jersey's denial of…

BOSTON SCIENTIFIC CORP · COURT-RULING filed Jun 16, 2026 at 20:00 ET

At the news

BEARISHIMPACT 5/10

COURT-RULING filed Jun 16, 2026 at 20:00 ET

The Federal Circuit affirmed the District of New Jersey's denial of Boston Scientific's (BSX) motion for a preliminary injunction that would have blocked Stryker (SYK) from launching its OptaBlate BVN device. The appeals court found substantial questions regarding whether Stryker induces infringement of BSX's '166 patent, specifically whether the accused device's access cannula 'reaches' the cancellous bone as required. The ruling clears a near-term competitive threat to Stryker but keeps the underlying patent case alive for a full trial on the merits.

  • Federal Circuit affirmed denial of preliminary injunction against Stryker's OptaBlate BVN device.
  • Court held there are substantial questions of fact regarding whether Stryker induces infringement of claims 16 and 21 of U.S. Patent No. 12,303,166.
  • District court's tentative claim construction that 'reaches' means 'touches or extends to' the cancellous bone was not an abuse of discretion.
  • Evidence of Stryker's physician instructions was ambiguous, slides, imaging, and IFU diagrams did not clearly show direct infringement.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access